Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Editas Medicine
Biotech
Editas prioritizes in vivo therapies, seeks reni-cel partner
Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda.
James Waldron
Oct 22, 2024 9:39am
Editas cashes in on Vertex Cas9 licensing agreement for $57M
Oct 4, 2024 5:06am
How Editas 'dragged' new CSO over after 37 years at Biogen
May 10, 2024 11:08am
JPM24, Day 3: Gene editors talk BD; Roivant has cash to spend
Jan 10, 2024 4:38pm
Vertex pays Editas $100M to use gene-editing tech
Dec 13, 2023 12:46pm
ASH: Editas shares data for mid-stage sickle cell disease asset
Dec 11, 2023 2:33pm
